Skip to main content

BIOengineered grafts for Cartilage Healing In Patients (BIO-CHIP)

Objective

Spontaneous healing of articular cartilage injuries is poor and untreated defects predispose to osteoarthritis. Current therapies, including innovative autologous cell-based treatments, cannot predictably and reproducibly restore cartilage structure and function.
BIOCHIP will carry out a multicenter, prospective phase II clinical trial to treat knee cartilage injuries using engineered grafts based on autologous nasal chondrocytes (NC). As compared to typically employed articular chondrocytes, NC have a higher and more reproducible capacity to generate mature cartilage tissues. Importantly, molecular/mechanical characterization, large size animal studies and a phase I trial carried out by BIOCHIP partners have already shown the compatibility of NC upon implantation in a joint, with promising preliminary clinical results.
BIO-CHIP’s specific objectives are:
(1) To test the hypothesis that the maturation of NC-based cartilage grafts improves the clinical efficacy in the treatment of cartilage lesions (108 patients will be recruited to reach statistical significance)
(2) To extend the range of clinical indications of NC-based grafts to so far untreatable pre-osteoarthritic lesions (‘kissing’ cartilage lesions in a sheep model)
BIO-CHIP capitalizes on clinical experience of 4 reference centers for cartilage surgery, on established GMP manufacturing capacity and on preparation for commercial exploitation by a strong orthopedic device company. Demonstration of therapeutic efficacy of the new treatment will address a large clinical need (over 2 million cartilage defects/year worldwide), improve quality of life (reduce pain & disability in the young, delay prosthetic implants in the elderly), exploit a commercial opportunity (prospected revenues of up to 130 million €/year) and reduce healthcare costs (estimated 12,000€ healthcare savings/procedure). BIO-CHIP will consolidate the currently leading role of Europe in the development of cell-based cartilage regeneration strate

Field of science

  • /medical and health sciences/clinical medicine/surgery
  • /medical and health sciences/medical biotechnology/medical bioproducts/implants

Call for proposal

H2020-PHC-2015-single-stage_RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

UNIVERSITAT BASEL
Address
Petersplatz 1
4051 Basel
Switzerland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 0

Participants (7)

UNIVERSITAETSKLINIKUM FREIBURG
Germany
EU contribution
€ 446 931,25
Address
Hugstetter Strasse 49
79106 Freiburg
Activity type
Higher or Secondary Education Establishments
SVEUCILISTE U ZAGREBU MEDICINSKI FAKULTET
Croatia
EU contribution
€ 967 000
Address
Salata 3
10 000 Zagreb
Activity type
Higher or Secondary Education Establishments
ISTITUTO ORTOPEDICO GALEAZZI SPA
Italy
EU contribution
€ 341 201,25
Address
Via Riccardo Galeazzi 4
20161 Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Germany
EU contribution
€ 1 204 593,75
Address
Hansastrasse 27C
80686 Munchen
Activity type
Research Organisations
MEDACTA INTERNATIONAL SA
Switzerland
EU contribution
€ 0
Address
Strada Regina
6874 Castel San Pietro
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK
France
EU contribution
€ 53 056,25
Address
5 Rue Watt
75013 Paris
Activity type
Research Organisations
JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG
Germany
EU contribution
€ 39 053,75
Address
Sanderring 2
97070 Wuerzburg
Activity type
Higher or Secondary Education Establishments